CRISPR Therapeutics AG
Stock Details
Is it expensive?
Market Cap
5.00B
Trailing P/E Ratio
-8.01
Forward P/E Ratio
-14.75
PEG Ratio
0.42
3.84B
-7.23
Price-to-Sales (TTM)
1.34K
3.03
18.83
Is it profitable?
4.10M
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
-4,494.90%
Diluted EPS (TTM)
-6.17
-31.21%
Is it growing?
68.60%
0.00%
Is it risky?
1.74
43.41
787.64M
17.97
Who owns it?
79.20%
5.91%
32.41%
96.39M
96.03M
Does it pay?
0.00%
0.00%
--
--
How much cash?
2.44B
-399.96M
-260.90M
25.32
- Price
- 51.84
- Percent Change
- -5.11 (8.97%)
- Previous Close
- 56.95
- Open
- 55.96
- Low
- 51.15
- High
- 55.96
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$51.84
From 52W Low
+40.03%
From 52W High
-33.94%
Today
-8.97%
1Y Change
+23.84%
6M
$57.36
3M
$56.50
1M
$55.08
Today
$51.84
From 52W Low
+40.03%
From 52W High
-33.94%
Today
-8.97%
1Y Change
+23.84%
6M
$57.36
3M
$56.50
1M
$55.08
Today
$51.84
Below Average
within its 1-year price range
$51.84
Multi-Timeframe Analysis (MTA)
Downtrend
Most timeframes point down. One conflicting period introduces some uncertainty, but the overall direction is negative. Weaker than a Strong Downtrend, but still a bearish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-5.9%
3M
-8.2%
6M
-9.6%
1Y
+23.8%
Rate of Change (ROC)
Accelerating
Price is falling 7.4x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- CRISPR Therapeutics AG
- Founded
- 2013
- CEO
- Samarth Kulkarni
- Employees
- 393
- Fiscal Year End
- Dec 31, 2024
- Address
Baarerstrasse 14
Zug
6300
Switzerland
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.crisprtx.com
Indicators
Operating Cash Flow
-399.96M
Net Income
-568.53M
Mixed Signal
0.70
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Indicators
Operating Cash Flow
-399.96M
Net Income
-568.53M
Mixed Signal
0.70
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Market Cap
5.00B
Trailing P/E Ratio
-8.01
Forward P/E Ratio
-14.75
PEG Ratio
0.42
3.84B
-7.23
Price-to-Sales (TTM)
1.34K
3.03
18.83
Is it profitable?
4.10M
Net Profit Margin (TTM)
0.00%
Gross Profit Margin
-4,494.90%
Diluted EPS (TTM)
-6.17
-31.21%
Is it growing?
68.60%
0.00%
Is it risky?
1.74
43.41
787.64M
17.97
Who owns it?
79.20%
5.91%
32.41%
96.39M
96.03M
Does it pay?
0.00%
0.00%
--
--
How much cash?
2.44B
-399.96M
-260.90M
25.32
- Price
- 51.84
- Percent Change
- -5.11 (8.97%)
- Previous Close
- 56.95
- Open
- 55.96
- Low
- 51.15
- High
- 55.96
52-Week Range Position (52WRP)
Below Average
Below Average
within its 1-year price range
$51.84
From 52W Low
+40.03%
From 52W High
-33.94%
Today
-8.97%
1Y Change
+23.84%
6M
$57.36
3M
$56.50
1M
$55.08
Today
$51.84
From 52W Low
+40.03%
From 52W High
-33.94%
Today
-8.97%
1Y Change
+23.84%
6M
$57.36
3M
$56.50
1M
$55.08
Today
$51.84
Below Average
within its 1-year price range
$51.84
Multi-Timeframe Analysis (MTA)
Downtrend
Most timeframes point down. One conflicting period introduces some uncertainty, but the overall direction is negative. Weaker than a Strong Downtrend, but still a bearish signal. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-5.9%
3M
-8.2%
6M
-9.6%
1Y
+23.8%
Rate of Change (ROC)
Accelerating
Price is falling 7.4x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- CRISPR Therapeutics AG
- Founded
- 2013
- CEO
- Samarth Kulkarni
- Employees
- 393
- Fiscal Year End
- Dec 31, 2024
- Address
Baarerstrasse 14
Zug
6300
Switzerland
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.crisprtx.com